No adverse event; 7 doses of Moderna monovalent lot number 055A22A, expiration date 2.2.23, was administered to patients. first Moderna dose on 11-Sep-2022 and Second Moderna dose on 27-Feb-2023; This spontaneous case was reported by another health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 055A22A, expiration date 2.2.23, was administered to patients.), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first Moderna dose on 11-Sep-2022 and Second Moderna dose on 27-Feb-2023) and NO ADVERSE EVENT (No adverse event) in a 25-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 055A22A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 11-Sep-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 27-Feb-2023, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to .5 milliliter. On 27-Feb-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 055A22A, expiration date 2.2.23, was administered to patients.) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first Moderna dose on 11-Sep-2022 and Second Moderna dose on 27-Feb-2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 055A22A, expiration date 2.2.23, was administered to patients.), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first Moderna dose on 11-Sep-2022 and Second Moderna dose on 27-Feb-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 055A22A, expiration date 2.2.23, was administered to patients.) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first Moderna dose on 11-Sep-2022 and Second Moderna dose on 27-Feb-2023).    No concomitant medications were reported.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  It was reported that 7 doses of Monovalent vaccine was administered to the patients on 27-Feb-2023 after manufacturer date of expiry.  The vaccine was frozen with no known temperature excursion before being thawed on 27-Feb-2023 for administration. The vial was initially stored in the refrigerator on 27-Feb-2023. The vial had not undergone any temperature excursion.   No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-713030, US-MODERNATX, INC.-MOD-2023-713149, US-MODERNATX, INC.-MOD-2023-713031, US-MODERNATX, INC.-MOD-2023-713027, US-MODERNATX, INC.-MOD-2023-712974 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-713030:Same reporter US-MODERNATX, INC.-MOD-2023-713149:Same reporter US-MODERNATX, INC.-MOD-2023-713027:Same reporter US-MODERNATX, INC.-MOD-2023-713031:Same reporter US-MODERNATX, INC.-MOD-2023-712974:Same reporter